Exelixis Announces US FDA Accepts Investigational New Drug Application for XB002 in Patients …,

… compared with earlier tissue factor-targeting ADCs; Exelixis’ plans to initiate a phase 1 clinical trial evaluating XB002 in patients with advanced solid …, … compared with earlier tissue factor-targeting ADCs; Exelixis’ plans to initiate a phase 1 clinical trial evaluating XB002 in patients with advanced solid …, Read More

Scroll to Top